Boston Oncology and King Fahd Medical City (KFMC) Partner to Advance Localized Cell & Gene Therapy in Saudi Arabia
In a landmark initiative poised to transform healthcare in the Kingdom of Saudi Arabia, Boston Oncology and King Fahd Medical City (KFMC) have signed a Letter of Intent to collaborate on the localization of Cell & Gene Therapy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731424463/en/
Representatives from Boston Oncology and King Fahd Medical City (KFMC), along with His Excellency Eng. Abdulaziz AlRamaih, Deputy Minister of Health for Planning and Development, at the signing ceremony for the partnership to advance localized Cell & Gene Therapy in Saudi Arabia. (Photo: Business Wire)
The signing ceremony, attended by His Excellency Eng. Abdulaziz AlRamaih, Deputy Minister of Health for Planning and Development, marks a significant step forward in advancing the Kingdom’s medical capabilities and achieving the ambitious goals set forth in Vision 2030.
A Milestone in Healthcare Transformation
Dr. Fahad Al-Ghofaili, KFMC CEO, expressed his enthusiasm: “Localizing Cell & Gene Therapy in KFMC is an important step to increase local capabilities in advanced treatments and medical technologies, contributing to the goals of the Healthcare Transformation Project.” [Translated from Arabic]
Impact for Patients
Boston Oncology, renowned for its customer-centered model, brings extensive expertise in localizing technology. Laser-focused on the real-world needs of patients and hospitals, Boston Oncology is positioned to provide cutting-edge technologies and Cell & Gene Therapies through this partnership. This collaboration will establish a local treatment option, relieving bottlenecks in therapy provision and improving patient outcomes. The resulting Research & Development and clinical trials will significantly contribute to innovative advancements in the healthcare sector of Saudi Arabia.
Dr. Abdullah Baaj, CEO of Boston Oncology, described the partnership: “KFMC brings world-class clinicians and infrastructure, making it a destination for patients throughout the region. Joining forces to localize Cell & Gene Therapy is a transformative step towards our mission to impact the lives of one billion patients.”
About Boston Oncology Cell & Gene Therapy
Boston Oncology is an innovative life science company with a mission to impact the lives of one billion patients by 2030. With corporate headquarters in Cambridge, Massachusetts, and operations throughout the world, the company is focused on bringing patient-centered solutions and advanced treatment modalities to growing markets. Its new Cell & Gene Therapy entity establishes a fully localized offering to deliver personalized treatments that address the unique genetic profiles of patients. By partnering with leading medical institutions and leveraging leading-edge technologies, Boston Oncology CGT is expanding the company’s legacy of transformative advancements in healthcare.
Learn more at https://bostononcology.com/.
About King Fahd Medical City
King Fahad Medical City (KFMC) in Riyadh, Saudi Arabia, stands as one of the largest and most rapidly expanding medical complexes in the Middle East, with a capacity of 1,200 beds. Operating within the second health cluster, KFMC consists of four hospitals and four specialized medical centers, offering comprehensive healthcare services. Known for its advanced medical technologies and high standard of care, KFMC serves over 30,000 inpatients and 500,000 outpatients annually. The institution is committed to excellence in clinical services, medical education, research, and continuous improvement in healthcare.
Learn more at https://www.kfmc.med.sa/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731424463/en/
Contacts
Boston Oncology Public Relations:
bo_cgt@bostononcology.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The smarter E AWARD 2025: Energy Transition Pioneers Shortlisted20.3.2025 14:53:00 CET | Press Release
The winners of The smarter E AWARD 2025 will be honored on 6 May at the International Congress Center Messe München. The finalists are the following. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320037540/en/ The finalists for The smarter E AWARD 2025 have been announced in the five categories. ©Solar Promotion GmbH Finalists in the Photovoltaics category 7Secondsolar (South Africa) with its AUTOPV planning software solution Aevy (Norway) with its Aevy asset management platform Aiko Energy (China) with its ABC INFINITE PV module Anhui Huasun Energy (China) with its Kunlun Series Ultra-high Bifaciality HJT solar module LONGi Solar Technology (China) with its Hi-MO X10 module MBJ Solutions (Germany) with its MBJ Sunlike Lab solar simulator Seaward Electronic (UK) with its PV:1525-IV testing device Sungrow Power Supply (China) with its SG350HX-20 string inverter Sunmaxx PVT (Germany) with its Sunmaxx PX-1 combination modul
Experian Assistant Wins 2025 FinTech Breakthrough Award for Analytics Innovation20.3.2025 14:00:00 CET | Press Release
Experian, a leading global data and technology company, today announced that Experian Assistant, an agentic AI-powered solution that greatly accelerates the data-modeling lifecycle, has won the 2025 FinTech Breakthrough Award for Analytics Innovation. For the second consecutive year, Experian received this prestigious award that recognizes those “who are dedicated to reshaping the FinTech industry and improving people’s lives through innovative technologies.” Experian Assistant enables financial institutions to perform data exploration, build and deploy models, monitor their performance, and increase speed to market to launch new offerings. Integrated with Experian Ascend Platform™, the solution greatly accelerates the modeling lifecycle, slashing model-development times from months to days and — in some cases — hours. “To stay ahead of their competition, financial institutions need a solution to quickly go from ideas to data and into production,” said Shri Santhanam, Executive Vice Pr
Caldera Medical Acquires Ethicon’s GYNECARE TVT ™ Family of Products in Transformational Expansion Globally for Women’s Health Company20.3.2025 14:00:00 CET | Press Release
Caldera Medical, a leader in women's health medical devices, has acquired Ethicon’s Gynecare TVT™ family of products and will transition the products in the coming months. This strategic milestone builds on Caldera Medical’s 23-year commitment to delivering best-in-class therapies that improve the quality of life for women worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320644274/en/ Caldera Medical is expanding its commitment to women’s health with the acquisition of Ethicon’s Gynecare TVT™ family of products! With over two decades of clinical data and trusted efficacy, TVT has been a gold standard in minimally invasive treatment for stress urinary incontinence (SUI). This acquisition ensures a seamless transition for surgeons, patients, and partners, as we maintain the same manufacturing, materials, and dedicated team behind these life-changing products. Our mission is clear: expanding access to proven pelvic
Cardiac Dimensions Raises $53 Million Series E Financing20.3.2025 14:00:00 CET | Press Release
Cardiac Dimensions®, a leader in minimally invasive treatments for heart failure and functional mitral regurgitation (FMR), today announced the close of an oversubscribed $53 million Series E financing round led by Ally Bridge Group with significant participation from existing investors. This financing will fund the completion of the EMPOWER Trial U.S. pivotal study and support the continued commercialization of the innovative Carillon Mitral Contour System®. “Cardiac Dimensions is uniquely positioned to provide a safe, simple, and effective solution for heart failure patients suffering from FMR. A financing of this magnitude reflects the strong conviction of Ally Bridge, as well as our existing insiders, in the Carillon® therapy’s ability to play a central role in the treatment of this high-need patient population,” said Rick Wypych, president and CEO of Cardiac Dimensions. “With these additional resources, we are also well-positioned to continue our global commercial expansion of the
Mercans Partners with Deloitte to Build a Best-in-Class Quality and Risk Management Framework20.3.2025 13:04:00 CET | Press Release
Mercans, a global leader in payroll and compliance solutions, is proud to announce a strategic partnership with Deloitte, one of the world’s foremost professional services firms, to develop and implement a best-in-class Quality Management and Risk Framework. As a company that places compliance at the heart of everything we do, Mercans continues to invest in world-class systems that exceed global standards and anticipate evolving regulations. This collaboration with Deloitte marks a significant step in strengthening our internal controls, governance, and quality assurance, ensuring that our clients can always rely on secure, compliant, and future-ready solutions. “Compliance is a constantly evolving landscape, and we believe in staying ahead of the curve. By joining forces with Deloitte, we’re not only reinforcing our commitment to excellence but also setting new benchmarks for the industry,” said Tatjana Domovits, CEO of Mercans. “This partnership ensures that our clients can continue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom